% | $
Quotes you view appear here for quick access.

VIVUS Inc. Message Board

  • diamondbacktrdr diamondbacktrdr Jan 11, 2013 5:20 PM Flag


    But VIVUS (NASDAQ: VVUS ) only reported the number of prescriptions for its obesity drug, Qsymia, that launched last year. While a 68% month-over-month increase is pretty impressive, the actual number of prescriptions -- about 13,000 for the four weeks ending Dec 21. -- is pretty pathetic.

    It's understandable why VIVUS might not want to point that out that sales for the quarter will likely be under $5 million. And the sales number could be even worse since VIVUS has been giving away a two-week supply of the drug to encourage patients to get started. VIVUS can't hide the sales number forever. Expect its fourth-quarter earnings call next month.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.37-0.13(-8.67%)May 4 4:00 PMEDT